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MicroRNA-200b Regulates Vascular Endothelial Growth
Factor–Mediated Alterations in Diabetic Retinopathy
Kara McArthur, Biao Feng, Yuexiu Wu, Shali Chen, and Subrata Chakrabarti
OBJECTIVE—Diabetic retinopathy (DR) is a leading cause of
blindness. Increased vascular endothelial growth factor (VEGF),
promoting angiogenesis and increased permeability, is a key mech-
anistic abnormality in DR. We investigated microRNA (miRNA)
alterations in DR with speciﬁc focus on miR-200b, and its
downstream target, VEGF.
RESEARCH DESIGN AND METHODS—miRNA expression
proﬁling microarray was used to examine the retinas of strepto-
zotocin-induced diabetic rats. Expressions of speciﬁc miRNAs
were veriﬁed with PCR in the rat retina and in glucose-exposed en-
dothelial cells. A target search, based on sequence complementar-
ities, identiﬁed speciﬁc targets. We analyzed mRNA levels and
protein expression in endothelial cells from large vessels and ret-
inal capillaries and in the rat retina, with or without injection
of miR-200b mimic or antagomir. Localization of miR-200b and
its functional analysis in the rat and human retinas were
performed.
RESULTS—Alteration of several miRNAs, including downregu-
lation of miR-200b, were observed in the retina in diabetes. Such
downregulation was validated in the retina of diabetic rats and in
endothelial cells incubated in glucose. In parallel, VEGF (target
of miR-200b) mRNA and protein were elevated. In the retina,
miR-200b was localized in neuronal, glial, and vascular elements.
Transfection of endothelial cells and intravitreal injection of miR-
200b mimic prevented diabetes-induced increased VEGF mRNA
and protein. Also prevented were glucose-induced increased
permeability and angiogenesis. Furthermore, transfection of miR-
200b antagonists (antagomir) led to increased VEGF production.
Similar alterations were seen in the human retina.
CONCLUSIONS—These studies show a novel mechanism in-
volving miR-200b in DR. Identiﬁcation of such mechanisms may
lead to the development of novel miRNA-based therapy. Diabetes
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D
espite the identiﬁcation of multiple pathoge-
netic mechanisms in a complex problem like
diabetic retinopathy (DR), limited success has
been achieved in its medical treatment. Vascu-
lar endothelial cells (ECs) undergo a series of metabolic
changes in response to sustained hyperglycemia in di-
abetes. These metabolic derangements cause the activa-
tion of transcription factors and augmented expression of
several growth factors and vasoactive factors, including
vascular endothelial growth factor (VEGF), resulting in
structural and functional alteration in the retina (1,2).
Small, nonprotein-coding microRNAs (miRNAs) are en-
dogenous regulators of gene expression and have been
implicated in a variety of cellular physiologic and patho-
logic processes (3,4). The miRNA molecules are synthe-
sized in the nucleus through RNA polymerase II. They
are then processed to precursor miRNAs (70–100 nucleo-
tides, hairpin-shaped) in the nucleus by RNAse III Dorsha
and DiGeorge syndrome critical region 8 (DGCR8). The
miRNAs are then exported to the cytoplasm by exportin 5.
Finally, an active form (;20–25 nucleotides) is produced in
the cytoplasm after further processing by Dicer. MiRNAs
have signiﬁcant effects on the regulation of gene expres-
sion. They bind to the speciﬁc mRNA targets, causing their
degradation or translational repression (3–5). Several in-
vestigators have used overexpression experiments to dem-
onstrate the importance of miRNAs in diverse cellular
processes (6). Other epigenetic mechanisms may play a
fundamental role in the regulation of miRNAs (3–5).
Hyperglycemia is responsible for the initiation and the
progression of chronic diabetes complications contribut-
ing to the structural and functional changes in the retina
and other organs (1,2,7). A number of growth factors and
vasoactive factors are increased in response to hypergly-
cemia, including endothelins and VEGF (7). Dysfunction of
ECs is the primary cellular pathology in chronic diabetes
complications. ECs undergo functional alterations, including
increased proliferation that causes neovascularization in
response to VEGF (8). VEGF has various isoforms, ranging
from 121 to 206 amino acids in length, with VEGF165 the
predominant form in humans (8,9). VEGF165 binds to cell
surface receptor tyrosine kinases: VEGFR-1 (ﬂt1) and
VEGFR-2 (ﬂk-1; KDR) (10). These receptors are mainly
found on ECs, where VEGFR-1 mediates vessel perme-
ability and VEGFR-2 is involved in angiogenesis (10,11).
Hence, VEGF-mediated alterations are of signiﬁcance in
the early (vascular permeability) as well as the late stages
(neovascularization) in DR.
No studies have speciﬁcally examined the role of miRNAs
in DR. We investigated whether miRNA alterations are in-
volved in DR. On the basis of our initial ﬁndings, we fur-
ther investigated the role speciﬁc miRNA (i.e., miR-200b in
DR). Because VEGF is a target of miR-200b, we explored
this relationship. We have previously demonstrated that
diabetes-induced vasoactive factor production is also me-
diated by transcription coactivator p300 (12). Because this
epigenetic alteration may play a role in miRNA action,
we further explored the relationship. To examine these
changes, we used a combination of in vivo and in vitro
approaches. We used cultured ECs and streptozotocin
(STZ)-induced diabetic rats. We further used human archi-
val material to examine the possibilities of such changes
in human DR.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Animal studies. All animals were cared for according to the Guiding Prin-
ciple in the Care and Use of Animals. All experiments were approved by the
University of Western Ontario Council on Animal Care Committee. Male SD
rats (200–250 g) were obtained from the Charles River Colony (Wilmington,
MA) and were randomly divided into control and diabetic groups. Methods of
diabetes induction and monitoring have previously been described (13). After
4 weeks, the animals (n = 6/group) were killed. The retinal tissues were snap-
frozen for gene expression and miRNA analysis or were placed in 10% formalin
for embedding in parafﬁn.
Intraocular injection of miRNA mimic and antagomir. After the onset of
STZ-induced diabetes miRIDIAN miRNA mimic or antagomir (Dharmacon,
Lafayette, CO) for miR-200b and the negative controls (scrambled) were in-
travitreally injected (1.4 mg/week, 4 weeks) using the Lipofectin Reagent (Life
Technologies, Carlsbad, CA) (14). Control rats were injected with the same
volume of saline and Lipofectin Reagent. Custom miRNA mimics or antagomir
were synthesized by Dharmacon based on mature miRNA sequences of hsa-
miR-200b (59-UAAUACUGCCUGGUAAUGAUGAC-39) and scrambled control
(59-UCACAACCUCCUAGAAAGAGUAGA-39). Intravitreal p300 small interfering
RNA (siRNA) injection has previously been described (14). The animals were
killed in week 5, and the retinal tissues were collected, as above.
Cell culture. Human umbilical veinECs (HUVECs;ATCC, Manassas,VA) were
used. The details of cell culture and p300 siRNA transfection have previously
been described (12,14). Similar methods were used for transfection of miRNA
mimics and antagomir. Bovine retinal capillary ECs (BRECs; VEC Technolo-
gies, Rensselaer, NY) were grown in the ﬁbronectin-coated ﬂask in a deﬁned
EC growth medium (MCDB-131 complete, VEC Technologies). At 24 h before
transfection, the cells were passaged in the six-well plate coated with ﬁbro-
nectin (Sigma, St. Louis, MO). The culture conditions have previously been
described (15,16). For transfection of BRECs, a 780-bp fragment containing
mouse miR-200b locus on chromosome 4 was cloned from mouse genomic
DNA into the pcDNA3.1(+) vector using restriction enzymes KpnI and XbaI.
The plasmids (2 mg) were transfected into the BRECs using lipofectamin 2000
for 24 h, and then the cells were collected for analysis.
Human embryonic kidney (HEK293A) cells (ATCC) were used as previously
described (17). All cell culture experiments were performed in triplicate for
four times or more. All reagents were obtained from Sigma Chemicals (Oak-
ville, ON, Canada), unless otherwise speciﬁed.
MiRNA microarray analysis. MiRNAs were extracted using the mirVana
miRNA isolation kit (Ambion, Austin, TX) according to the manufacturer’s
instruction. Custom analysis of miRNA expression proﬁling from rat retinal
samples (n = 3/group) were performed by Asuragen Inc. (Austin, TX).
MiRNA target search. Open-sourced software using different algorithms based
on sequence complementarity, such as TargetScan 5.1 (www.targetscan.org) and
miRanda (www.microrna.org), were used for miRNA target predictions.
Luciferase assay. The 39-untranslated regions (UTR) of VEGF from rat and
human genomes were used with appended SacI and HindIII restriction sites in
the forward and reverse position, respectively. The primers for human VEGF
39UTR cloning are: sense, AGAGCTCCCCGGCGAAGAGAAGAGAC; antisense,
TCAAGCTTGGAGGGCAGAGCTGAGTGTTA. The primers for rat VEGF 39UTR
cloning are: sense, AGAGCTCGGGTCCTGGCAAAGAGAAG; antisense, TCAA
GCTTGGAGGGCAGAGCTGAGTGTTA.
ThetargetgeneinsertwasthenligatedintothepMIR-REPORTvector(Ambion),
which was used to transform DH5a competent cells (Invitrogen, Burlington, ON,
Canada). The DNA sequence of the cloned product was conﬁrmed by se-
quencing. The pMIR_VEGF 39UTR, miR-200b mimic (or scrambled) and pMIR
REPORT luciferase vector reporter and control vector containing b-galactosidase
with cytomegalovirus promoter were then cotransfected into the 293A cells.
Nucleotide substitutions were inserted by PCR. The primers for human and rat
VEGF 39UTR mutation cloning are listed in the Supplementary Table. Luciferase
activity was measured 48 h after transfection using the Dual-Light Chemilumi-
nescent Reporter Gene Assay System (Applied Biosystems, Carlsbad, CA) fol-
lowing the manufacturer’s instructions. Luciferase activity was read using
Chemiluminescent SpectraMax M5 (Molecular Devices, Sunnyvale, CA) (17).
MiRNA analysis. RNA was extracted with the mirVana miRNA isolation kit
(Ambion). Total RNA (50 ng) was used for cDNA synthesis with TaqMan
MicroRNA Assay Reverse Transcription Primer and MultiScribe reverse tran-
scriptase(AppliedBiosystems).Speciﬁcprimers werecustomsynthesizedbased
on the mature miR-200b sequence (see above), mature miR-144 sequence
(UACAGUAUAGAUGAUGUACU), mature miR-30a-3p sequence (CUUUCAG
UCGGAUGUUUGCAGC), mature miR-429 sequence (UAAUACUGUCUGGU
AAAACCGU), mature miR-200c sequence (UAAUACUGCCGGGUAAUGAUGG),
and mature miR-200a sequence (UAACACUGUCUGGUAACGAUGU). Real-time
qRT-PCR was performed with TaqMan MicroRNA Assay using the LightCycler
(Roche Diagnostic, Laval, QC, Canada) as described, and the data were nor-
malized to RNU6B (18).
mRNA analysis. RNA was extracted with TRIzol reagent (Invitrogen) as pre-
viously described. Real time RT-PCR for mRNAs was done in the LightCycler
(Roche Diagnostics). The data were normalized to the housekeeping gene
b-actin or 18S rRNA. These methods have previously been described (12,14).
ELISA. ELISA for VEGF was performed using a commercially available kit for
rat VEGF (ALPCO, Salem, NH; R&D Systems, Minneapolis, MN) according to
the manufacturers’ instructions (12).
Permeability assay. HUVECs were seeded onto inserts (1-mm pores) in
24-well plates, with or without incubation with speciﬁc reagents for 24 h, and
were tested for vascular permeability using the In Vitro Vascular Permeability
Assay Kit (Millipore, Billerica, MA) according to the manufacturer’s instruc-
tions (19).
Angiogenesis assay. An in vitro Angiogenesis Assay Kit (Chemicon, Billerica,
MA) was used to evaluate tube formation of HUVECs. Tube formation was
quantiﬁed using branch point counting with Inﬁnity Capture Application 3.5.1
software on aLeicaMicrosystems(Bannockburn, IL)inverted microscope (20).
Immunohistochemistry. Rat and human retinal sections were immunocyto-
chemically stained for albumin to examine for increased vascular permeability
using anti-human albumin antibody (1:500; Abcam, Cambridge, MA). These
methods have previously been described (21,22). Quantiﬁcation of diffuse
retinal staining was done by an investigator in a masked fashion using an
arbitrary scale (score 0 = no extravascular stain of retinal tissues, score 1 =
mild extravascular stain of retinal tissues, score 2 = moderate extravascular
stain of retinal tissue, score 3 = marked extravascular stain of retinal tissues).
“No antibody” and isotype-matched IgG controls were used. CD34 (1:200;
Dako, Glostrup, Denmark) immunostain was used to identify capillary endo-
thelium.
In situ hybridization. Rat and human retinal sections were labeled for miR-
200b expression. Retinal tissue sections (5-mm thick) from formalin-ﬁxed,
parafﬁn-embedded blocks were transferred to positively charged slides to be
used for labeling. A 59 and 39 double DIG-labeled custom-made mercury Locked
Nucleic Acid (LNA) miRNA detection probe (Exiqon, Vedbaek, Denmark) was
used to detect miR-200b expression along with the In Situ Hybridization (ISH)
Kit (Biochain Institute, Hayward, CA) (23). Scrambled probes and no-probe
controls were used as controls.
Statistical analysis. Data are expressed as mean 6 SEM and were analyzed
by ANOVA, followed by Student t test with Bonferroni corrections or by
Student t test only, where appropriate. Differences were considered signiﬁcant
at values of P , 0.05.
RESULTS
Diabetes causes miRNA alterations in the retina.
Speculating that the altered expression of key genes in
diabetes may be partly regulated by miRNAs, we ﬁrst
searched for miRNAs whose expression changed in di-
abetes. To this end, we used an animal model of chronic
diabetes. STZ-induced diabetic rats exhibit molecular
and early structural and functional changes of DR (1,7,21).
To examine miRNA alteration in DR, we did a microar-
ray analysis of the retinal tissues from male STZ-induced
diabetic rats and age- and sex-matched controls after
1 month of diabetes. Diabetic animals showed hypergly-
cemia (serum glucose of rats with diabetes 19.2 6 4.7
mmol/L vs. controls 7.0 6 0.8 mmol/L, P , 0.005) and re-
duced body weight (rats with diabetes 372.0 6 34.7 g vs.
controls 445.7 6 17.4 g, P , 0.01). Retinal tissues of the
diabetic animals showed increased levels of VEGF mRNA
and protein as measured by qRT-PCR and ELISA (Fig. 1A
and B). This is in keeping with our previous studies (21).
We then extracted miRNAs from these tissues and per-
formed microarray analysis, which showed alterations of
multiple miRNAs in the retina of these animals (Fig. 1C).
We used open sourced software (www.TargetScan.org,
www.microrna.org, www.ebi.ac.uk1) for miRNA target
predictions to identify miRNAs associated with known
genes/proteins that are altered in DR. A VEGF targeting
miRNA, miR-200b, was signiﬁcantly downregulated in the
diabetic animals. We veriﬁed the downregulation of miR-
200b with qRT-PCR in the retina of diabetic animals (Fig. 1D).
Other members of miR-200b cluster, namely miR-200a and
miR-429, were not signiﬁcantly altered (miR-429, miR-200a)
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signiﬁcant alterations of miR-200a, miR-200c, and miR-429
were seen in the array. However, an additional RT-PCR
assay conﬁrmed that there were no alterations of miR-429,
miR-200a, and miR-200c in the retina in diabetes (Fig. 1E–G).
Hence, an association was established between miR-200b
downregulation and VEGF upregulation in DR. To test
the speciﬁcity of miR-200b regarding VEGF, we examined
whether ﬁbronectin (FN), another bioinformatics-based tar-
get of miR-200b and a protein of interest in DR, is regulated
by miR-200b. However, no direct regulation of FN by miR-
200b was observed (data not shown). We also validated
several other miRNAs (miR-144 and miR-30a-3p), which
qRT-PCR showed were upregulated in the retina of diabetic
animals (data not shown).
miR-200b regulates glucose-induced VEGF upregulation
in the ECs. To establish a cause-effect relationship, we
ﬁrst used an in vitro model system. Because ECs are the
primary cellular targets in DR, we used HUVECs in culture
to study the mechanistic aspects and the functional sig-
niﬁcance of miR-200b alterations. ECs exposed to high
levels of glucose (simulating hyperglycemia) recapitulate
molecular and functional features of diabetic vascular pa-
thologies (12,24). We ﬁrst determined whether exposure
of HUVECs to high levels of glucose causes changes in
miR-200b levels. Our results show that 25 mmol/L D-glucose
(HG), compared with 5 mmol/L D-glucose (LG), causes
as i g n i ﬁcant downregulation of miR-200b (Fig. 2A). These
levels of glucose were established using a dose-response
analysis of VEGF expression (data not shown) and by
FIG. 1. MiRNA and VEGF alteration in the retina in diabetes. Quantitative RT-PCR (A) and ELISA (B) analysis from nondiabetic control and
diabetic rat retinal tissue samples after 1 month of follow-up show increased levels of VEGF mRNA and protein. C: Volcano plot shows miRNA
alteration in control vs. diabetic (treated) rat retina after 1 month. Circles to the left of 21 difference line and to the right of the 1 difference line
are considered to have a fold-change >23 (x-axis is the log2 of the fold-change between two groups). The arrow indicates the location of miR-200b.
(Custom analysis using Asuragen miRNA system. Some of the highly expressed miRNAs represent putative miRNA sites, which require biological
characterization). Data array were validated with qRT-PCR analyses, which conﬁrmed downregulation of miR-200b in the retina of diabetic rats
compared with the nondiabetic controls (D) and no signiﬁcant changes in the expression of miR-429 (E), miR-200a (F), and miR-200c (G). The
miRNA data are expressed as a ratio to RNU6B (U6); mRNA levels are expressed as a ratio to 18S RNA, and normalized to controls. The error bars
show the SEM. *Signiﬁcantly different from the other group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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posed to 25 mmol/L D-glucose (HG) compared with 5 mmol/L D-glucose (LG), but not by 25 mmol/L L-glucose (osmotic control, OSM). B:T r a n s f e c t i o no f
endothelial cells with miR-200b mimics (but not the scrambled mimics) normalized HG-induced upregulation of VEGF. Glucose-like effect (VEGF
upregulation) was seen when cells in LG were transfected with miR-200b antagomir. OSM had no effect on VEGF expression. C:E f ﬁciency of miR-200b
mimic transfection as shown by increased miR-200b expression in the ECs after miR-200b mimic transfection compared with scrambled mimics. D:S i m i l a r
to HUVECs, BRECs showed glucose-induced miR-200b downregulation. E: Transfection of BRECs with miR-200b mimics (using miR-200b cloned in
PcDNA3.1 vector, but not by empty vector) normalizedH G - i n d u c e du p r e g u l a t i o no fV E G Fm R N Ae x p r e s s i o n .F:E f ﬁciency of miR-200b mimic transfection
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level was observed when the cells were challenged with 25
mmol/L L-glucose (OSM; Fig. 2A).
In parallel to decreased miR-200b upon exposure to HG,
mRNA levels of VEGF (measured by qRT-PCR) were in-
creased. Such increases were prevented by miR-200b
mimic transfection. Transfection efﬁciencies, assessed by
measuring miR-200b expression showed .10-fold increase
in intracellular miR-200b expression compared with scram-
bled miRNA transfection (Fig. 2C). However, transfection of
miR-200b antagomir in the cells in LG demonstrated gluco-
mimetic effects by upregulating VEGF transcripts (Fig. 2B)
To further establish a direct relevance of our ﬁndings in
the context of diabetic retinopathy, we examined whether
similar changes occur in the retinal capillary ECs. Our
results show that HG, compared with LG, causes a signiﬁ-
cant downregulation of miR-200b (Fig. 2D) in BRECs. In
parallel, VEGF mRNA was upregulated after exposure to
HG. Transfection of miR-200b mimics prevented glucose-
induced VEGF upregulation (Fig. 2E). Transfection efﬁ-
ciencies for miR-200b was conﬁrmed by analyzing the
abundance of miR-200b in these cells, which showed .20-
fold increase in intracellular miR-200b expression com-
pared with vector only transfection (Fig. 2F).
miR-200b regulates glucose-induced functional
alterations in the endothelial cells. We next examined
endothelial permeability and tube formation, two charac-
teristic functional effects of VEGF in this system. HUVECs
showed increased permeability and tube formation after
treatment with HG and VEGF peptide (Fig. 2G–J). To ex-
amine functional signiﬁcance of miR-200b, we transfected
miR-200b mimics (and scrambled controls) in HUVECs
exposed to HG. Transfection efﬁciency was conﬁrmed by
analyzing the abundance of miR-200b in these cells (Fig. 2C).
Glucose-induced increased endothelial permeability is a
characteristic alteration in early diabetic retinal micro-
angiopathy, which is mediated by VEGF. Upon miR-200b
mimic transfection, we observed a normalization of glucose-
induced upregulation of VEGF. Glucose-induced increased
endothelial permeability was further prevented by such
transfection (Fig. 2G and H). However, no effects were
seen after scrambled mimic transfection. In parallel, in-
cubation of the cells with VEGF peptide showed increased
permeability (Fig. 2G and H). Similarly, we did a tube for-
mation assay as a surrogate for angiogenesis. HG caused
increased tube formation in the ECs. Such changes were
also prevented by miR-200b mimic transfection but not by
scrambled mimic transfection (Fig. 2I and J). These results
established a direct regulatory relationship between miR-
200b on HG-induced VEGF expression and its functional
consequences.
To further validate miR-200b targeting of VEGF, we ex-
amined the binding of miR-200b with 39UTR of the VEGF
gene. Luciferase reporter plasmids were generated with a
constitutively active promoter containing cloned miR-200b
binding sites from human or rat VEGF 39-UTR or mutated
39-UTR. They were cotransfected in HEK-293A cells
with miR-200b mimic. Such transfection lead to ectopic
overexpression of miR-200b and a signiﬁcant reduction of
luciferase reporter activity compared with control vector
transfection, indicating its direct binding (Fig. 3B and C).
Scrambled miRNA elicited no effects. Mutated target se-
quence VEGF 39-UTR was also not responsive to miR-200b
(Fig. 3B and C).
miR-200b is present in the retina and regulates
diabetes-induced retinal VEGF upregulation. Having
established VEGF targeting by miR-200b in vitro, we tested
whether miR-200b targets VEGF in the diabetic animal
model. The miR-200b mimic was injected in the vitreous
cavity of one eye of the diabetic rats at 1.4 mg/week for
4 weeks, and the other eye received the same dose of
scrambled control. In a separate set of experiments, we
injected intravitreal miR-200b antagomir to nondiabetic
animals. This injection led to increased VEGF expression.
The level of VEGF mRNA and protein showed a signiﬁcant
decrease in miR-200b mimic-injected diabetic retinas
compared with the retinas injected with the scrambled
control (Fig. 4A and B). However, the nondiabetic rat ret-
inas injected with antigomir showed increased VEGF
mRNA and protein levels (Fig. 4A and B). Injection efﬁ-
ciency for the miR-200b mimic was conﬁrmed by demon-
strating the abundance of miR-200b in the retina after mimic
injection compared with the scramble control (Fig. 4C).
To study permeability changes, we measured albumin
permeation from the retinal vasculature using an albumin
immunostaining, as previously described (21,22). Our
ﬁndings show that diabetes-induced increased vascular
permeability was prevented by the miR-200b mimic in-
jection (Fig. 4D–G). No extravascular albumin was seen in
the control animals (score = 0). Diabetic animals demon-
strated a score of 2 to 3, indicating increased extravasated
albumin. However, scores of 0 to 1 were noted in eyes
injected with the miR-200b mimic, indicating prevention of
diabetes-induced increased vascular permeability by such
treatment. In situ hybridization studies using LNA probes
showed localization of miR-200b in the vascular endothe-
lium and in neuronal and glial elements in the retina of
nondiabetic rats. The expression of miR-200b was reduced
in the diabetic retina (Fig. 4H and I). No stains were seen
when scrambled or no-probe controls were used.
Glucose-induced reduced miR-200b mediates
upregulation of transcriptional coactivator p300. Re-
search has shown that miR-200b regulates epithelial to
mesenchymal transition in malignancies by controlling p300,
a transcription coactivator (26–28). We have previously
reported increased p300 in DR and glucose-exposed en-
dothelial cells (12–14), so we studied whether hypergly-
cemia changes p300 through miR-200b. Interestingly, miR-
200b mimic transfection prevented HG-induced p300 up-
regulation in the endothelial cells (Fig. 5A). However,
glucose-induced downregulation of miR-200b in the endo-
thelial cells was not corrected by p300 silencing (Fig. 5B).
To further examine whether some of the mechanisms of
miR-200b action is mediated through regulation of p300
in vivo, we examined p300 mRNA expression in the reti-
nal tissues after intravitreal injection of miR-200b mimics.
in the BREC was shown by increased miR-200b expression in these cells after miR-200b mimic transfection compared with vector control. HG-
induced and VEGF-mediated increased transendothelial permeability (G), duration-dependent data and at the end point (H) were prevented by
miR-200b mimic transfection. I: Similarly, glucose-induced EC tube formation was prevented by miR-200b mimic transfection. (Original magni-
ﬁcation 3400.) J: The quantiﬁcation of the tube formation assay is shown. Scram, scrambled miRNA; 200b, miR-200b mimic; 200b(A), 200b
antagomir; V, PcDNA3.1 vecto. *Signiﬁcantly different from LG or LG scram. +Signiﬁcantly different from HG or HG scram. **Signiﬁcantly dif-
ferent from other group(s). The miRNA levels are expressed as a ratio of RNU6B (U6) and normalized to LG; mRNA is expressed as a ratio to 18S
RNA and normalized to LG. The error bars show the SEM. (A high-quality color representation of this ﬁgure is available in the online issue.)
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prevented by miR-200b injection, suggesting another mech-
anisms by which miR-200b may act on vasoactive factors
(Fig. 5C).
miR-200b downregulation is present in human DR.
Finally, we examined human retinas in the enucleated eyes
from archival sources using in situ hybridization and
immunostains. We found reduced miR-200b (Fig. 6A and
B), and increased extravascular albumin (Fig. 6C and D)i n
the retinas from patients with diabetes. The cellular dis-
tribution of miR-200b was similar to that in the rat eyes
(Fig. 6A).
DISCUSSION
This study demonstrates a novel pathway causing VEGF
expression and subsequent alterations in the retina in di-
abetes. We have shown that high levels of glucose in di-
abetes causes downregulation of miR-200b, which controls
VEGF mRNA and protein levels, and increased permeability
both in vivo and in vitro. We were also able to prevent di-
abetes-induced, VEGF-mediated functional changes in the
ECs and in the retina by miR-200b mimic treatment.
We investigated the mechanisms at multiple levels of
complexities. After the initial identiﬁcation of miR-200b
alteration in the retina in diabetes, we used HUVECs to
identify the in vitro biologic signiﬁcance. Although these
cells are not of retinal origin, they are widely used as a
model for the study of endothelial abnormalities in several
diseases, including DR (12,14,19). However, in parallel we
investigated retinal capillary ECs and demonstrated similar
changes. After the in vitro studies, we used a well-established
animal model to identify the in vivo signiﬁcance. Finally,
we examined human tissue to investigate whether similar
changes are present in the human retina. This is the ﬁrst
study to investigate miRNAs in DR and directly demon-
strates a functional and potential therapeutic implication
of miR-200b in DR. We previously demonstrated the role of
miR-133a in diabetic cardiomyopathy (18), other inves-
tigators have shown the role of miR-192 in diabetic ne-
phropathy (29,30), and miR-200a was recently found to be
of importance in diabetic nephropathy (31).
Alterations of these miRNAs were not seen in this study.
Although our array analysis or PCR failed to demonstrate
alteration of VEGF targeting miR-429 or other molecules
with sequence similarities such as miR-200c, possibilities
of VEGF regulation by these or other miRNAs cannot be
completely excluded. In a complicated disease process
like DR, several regulatory mechanisms may come into
play, depending on the duration or severity of the disease,
or both. Further investigations are necessary to address
such issues.
The mechanisms by which hyperglycemia causes cellu-
lar damage are not fully understood. However, evidence
indicates that increased oxidative stress causing DNA
damage may be involved (2,26,32). Increased oxidative
stress causes the activation of the redox-sensitive tran-
scription factors and altered expression of a number of
genes, including VEGF. VEGF is a potent growth factor
responsible in mediating several abnormalities in the ret-
ina in diabetes. Under diabetic conditions, it acts to in-
crease vascular permeability in the early stages of DR and
ﬂuid accumulates in the retinal tissue, causing macu-
lar edema and exudate. VEGF also causes an increase in
FIG. 3. A: Alignment of VEGF 39-UTR (and mutated VEGF 39-UTR) sequence with mature miR-200b based on bioinformatics predictions (www.
TargetScan.org, www.microrna.org, www.ebi.ac.uk1). The 59 end of the mature miR-200b is the seed sequence and has perfect complementarity
with seven nucleotides of the 39-UTR of VEGF. In the mutated sequence (small caps identifying mutated nucleotides) such complementarity was
lost. B and C: Binding of miR-200b with VEGF promoter luciferase reporter assay shows dose-dependent binding of VEGF 39-UTR with miR-200b,
whereas mutated (mut) VEGF 39-UTR abrogated the inhibitory effects of miR-200b. Relative promoter activities were expressed as luminescence
units normalized for b-galactosidase expression. *Signiﬁcantly different from vector, scrambled (scram) or mut. VEGFH, human VEGF; VEGFR,
rat VEGF. (A high-quality color representation of this ﬁgure is available in the online issue.)
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Here we have shown that miR-200b, through VEGF, inﬂu-
ences both of these functional effects of VEGF in vitro and
in vivo.
MiRNAs are endogenous regulators produced as small,
nonprotein-coding RNAs and are highly conserved among
species (3,4,37). They mostly negatively regulate gene ex-
pression at the post-transcriptional level by interacting
with their target mRNA 39-UTR (3,37). Most target mRNA
predictions for miRNAs stem from computational analysis
examining sequence complementarity (3,37,38). With their
widespread involvement in several biologic processes,
miRNAs may have an important modulatory role in DR.
In keeping with our data, a previous study demonstrated
the presence of miR-200b in human and rat retina (39). This
study and our study demonstrating miR-200b expression in
FIG. 4. miR-200b–mediated alteration of retinal VEGF and its functional consequences. Levels of VEGF mRNA (A) and protein (B) in the control
and diabetic rat retina, with or without intravitreal injection of miR-200b mimic (200b) and scrambled mimic (Scram) show that upregulated VEGF
expression in the diabetic rat retina can be prevented by miR-200b mimics (but not by scrambled mimics). Intravitreal injection of miR-200b
antagomir (200b[A]) produced VEGF upregulation. C:E f ﬁciency of intravitreal delivery as demonstrated by increased retinal miR-200b expression
after intravitreal injection of miR-200b mimic compared with scrambled mimic. *Signiﬁcantly different from control. +Signiﬁcantly different from
diabetic or diabetic scram. The error bars show the SEM. D: Immunocytochemical stain on the control rat retina using antialbumin antibody shows
only intravascular albumin (brown chromogen arrow; score = 0). E: Similar stain in the diabetic rat retina resulted in intravascular reactivity
(arrow) and diffuse staining of the retina (score = 3), indicating increased vascular permeability. F: After intravitreal miR-200b injection, albumin
staining was only present in the intravascular compartment (arrow; score = 0). G: Negative control of E shows speciﬁcity of staining. No such
effects were seen after scrambled miR-200b injection (not shown). H: LNA-ISH study of retinal tissues in a control rat retina shows localization of
miR-200b (blue chromogen) in the retinal capillaries (arrow), ganglion cells (arrowheads), and in the cells of inner nuclear layer (large arrow),
both in the glial and neuronal elements. The inset shows an enlarged view of a capillary with miR-200b localization (arrow). I: LNA-ISH study of
retinal tissues in a diabetic rat retina (in similar orientation) show minimum (if any) expression of miR-200b (ALK Phos was used as chromogen
[blue] with no counterstain in LNA-ISH; DAB chromogen [brown] and hematoxylin counterstain in albumin stain). (Original magniﬁcation 3400 for
D–I.) (A high-quality digital representation of this ﬁgure is available in the online issue.)
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and may reﬂect a possible conserved functional role within
the mammalian retina. The potential role of miRNAs in
nondiabetic angiogenesis has further been investigated in
mice homozygous for a hypomorphic allele of Dicer. These
mice lacked angiogenesis and died in utero (40). Another
study found that a nonlethal Dicer hypomorphism caused
female mice to be sterile due to the failure of angiogenesis
in the corpus luteum (41). In a model of ischemic ocular
neovascularization, seven miRNAs were increased and
three were decreased in the retina (41). However, neovas-
cularization in DR may be different from nondiabetic neo-
vascularization with respect to miRNA. No alteration of
miR-200b was identiﬁed in such condition (42).
The regulatory role of miR-200b with p300 is further
interesting. It has been shown that miR-200 may regulate
p300, a histone aceylator and transcription coactivator in
malignancies (43). Other research indicated that in pan-
creatic ductal adenocarcinoma, six p300 targeting miRNAs,
including miR-200b, were downregulated in the highly
metastatic group (28). We have previously shown the role
of p300 in DR and other diabetes complications and that it
regulates multiple gene and protein expression in diabetes
(12,14). Such effects of p300 are mediated by its capacity
to control actions of a large number of transcription fac-
tors (12). This study showed novel miR-200b–mediated
mechanisms by which p300 is regulated in diabetes. Hence,
in addition to its direct inhibitory effects on hyperglycemia-
induced VEGF expression, miRNA may mediate such ef-
fects indirectly through p300. Such p300-mediated action of
FIG. 5. miR-200b regulates diabetes-induced p300 alteration. A: miR-
200b mimic (but not the scrambled mimics) transfection prevented
glucose-induced p300 mRNA upregulation in the HUVECs (please see
Fig. 2C regarding the efﬁciency of miR-200b mimic transfection). B:N o
effects of p300 siRNA transfection on miR-200b expression were seen.
C: Augmented retinal p300 mRNA expression in the diabetic rats
(compared with the controls) was prevented by intravitreal injection of
miR-200b mimic (200b) but not by scrambled mimic (Scram). (Please
see Fig. 4C regarding efﬁciency of intravitreal delivery). *Signiﬁcantly
different from control or LG (5 mmol/L D-glucose). +Signiﬁcantly dif-
ferent from diabetic or HG (25 mmol/L D-glucose). The error bars show
the SEM.
FIG. 6. miR-200b alteration present in human diabetic retinopathy.
A: LNA-ISH study of retinal tissues from nondiabetic human retina
shows localization of miR-200b in the cells of the inner nuclear layer
(arrowheads) and retinal capillaries (arrow). The inset (right) shows
an enlarged view of the same capillary with endothelial localization of
miR-200b (blue chromogen, arrow) and CD34 stain (brown chromogen)
from an adjacent section showing endothelium of the capillary. B: Ret-
inal tissues in a diabetic human retina (in similar orientation) show
minimal (if any) expression of miR-200b. C: Immunocytochemical stain
on the nondiabetic human retina using antialbumin antibody shows
intravascular albumin (arrow). D: Diabetic human retina showed in-
travascular albumin staining (arrow) and diffuse staining of the retina,
indicating increased vascular permeability. (ALK Phos was used as
chromogen [blue] with no counterstain in LNA-ISH; DAB chromogen
[brown] and hematoxylin counterstain in albumin stain.) (Original
magniﬁcation 3400.) (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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vasoactive factors (12).
Further experiments are needed to establish such a no-
tion, however. DR is a complex problem in which multi-
ple transcripts are altered, kicking off multiple abnormal
pathways. Targeting individual proteins for treatments of
DR have been tried for a long time and have failed in
clinical trials. From a mechanistic standpoint, one miRNA
regulates multiple genes, and targeting one or a few miRNAs
provides potential unique opportunities to prevent multi-
ple gene expression. We must point out that although our
initial studies showed alterations of multiple miRNAs in
the retina of diabetic rats, several of these were putative
miRNAs and their roles in gene regulation have not been
established. The challenge for miRNA research is also to
deﬁne the function of miRNAs in various tissues and dis-
ease states by identifying and validating target mRNAs (44).
The analysis of miRNA alteration in pathologic disease
states is becoming increasingly more common in research.
In summary, we identiﬁed miR-200b as a speciﬁc miRNA
in DR. We demonstrated, using investigations at several
levels of complexities, that miR-200b is important in reg-
ulation VEGF-mediated abnormalities in DR. Identiﬁcation
of such novel mechanisms will help us to better under-
stand the pathogenesis of DR and will eventually be
helpful in the formulation of speciﬁc adjuvant treatment.
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